ACADIA Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ACAD 41.69 +0.02 (0.05%)
price chart
HC Wainwright Maintains Buy on ACADIA Pharmaceuticals Inc. Following ...
In a research report issued yesterday, H.C. Wainwright analyst Andrew Fein maintained a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $50 price target, after having a meeting with management last week. Fein noted, “The main ...
ACADIA Pharmaceuticals's "Buy" Rating Reaffirmed at HC ...  Dakota Financial News
ACADIA Pharmaceuticals Rating Reiterated by HC Wainright (ACAD)  The Legacy
Analyst Price Target Update on ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): 8 Analyst have given the stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a near short term price target of $41.75.
Stock in Focus - ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)  Vanguard Tribune
Watch List for Investors: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), The ...  Property Mentor
Will ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Surprise Analysts?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is next slated to report earnings for the current quarter on 2015-08-04. Brokerages covering the stock are currently expecting the firm to earn $-0.3 per share based on the 8 covering brokerages weighted into ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Analyst Rating Update
Analysts at Zacks have given a short term rating of hold on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) with a rank of 3. The company has received an average rating of 1.38 from 8 brokerage firms.
ACADIA Pharmaceuticals Inc., ARIAD Pharmaceuticals, Inc. Mobbed by Option ...
Biotech stocks have been red hot lately, and today is no exception. Two names within that sector seeing sizable upside this afternoon -- and attracting attention from option bulls -- are ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Ariad ...
ACADIA Pharmaceuticals Inc. Price Target Update
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): 8 Analyst have given the stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a near short term price target of $41.75.
ACADIA Pharmaceuticals Inc. Short Interest Update  American Trade Journal
ACADIA Pharmaceuticals Upgraded to "Hold" at Zacks (ACAD)  Dakota Financial News
Company Shares of ACADIA Pharmaceuticals Inc. Rally 0.43%
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rose by 0.43% in the past week and 1.77% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 0.84% and the outperformance increases to 2.06% for the last 4 weeks.
Scorching Hot Biotech Stocks Tape - Novavax, Inc. (NASDAQ:NVAX), ACADIA ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) advanced +5.07% to finish last trading session at $41.88. The company, on June 16, 2015, reported the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID™ ...
Technical Report on ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
[Business Wire] ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)(TREND ANALYSIS) a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today ...
Company Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. Presents ...  Smarter Analyst
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences ...  MarketWatch
Should AbbVie, Inc. Buy Acadia Pharmaceuticals to Help Fight Parkinson's ...
Perhaps as a direct consequence of these issues, we witnessed the company's longtime CEO Uli Hacksell abruptly retire last month, even relinquishing his seat on the Board.